Short Interest in Heatwurx Inc. (NASDAQ:PCSA) Decreases By 65.4%

Heatwurx Inc. (NASDAQ:PCSA) was the recipient of a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 10,356 shares, a drop of 65.4% from the January 29th total of 29,972 shares. Based on an average trading volume of 66,959 shares, the short-interest ratio is currently 0.2 days. Approximately 0.5% of the shares of the stock are sold short. Approximately 0.5% of the shares of the stock are sold short. Based on an average trading volume of 66,959 shares, the short-interest ratio is currently 0.2 days.

Heatwurx Trading Up 6.9%

NASDAQ PCSA traded up $0.15 during trading hours on Thursday, hitting $2.25. 7,714 shares of the company’s stock were exchanged, compared to its average volume of 68,102. The stock has a 50-day simple moving average of $2.94 and a 200 day simple moving average of $5.29. The firm has a market cap of $5.10 million, a price-to-earnings ratio of -0.07 and a beta of 1.14. Heatwurx has a 1-year low of $1.76 and a 1-year high of $19.64.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Heatwurx from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $25.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.